Latest Insider Transactions at Genprex, Inc. (GNPX)
This section provides a real-time view of insider transactions for Genprex, Inc. (GNPX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Genprex, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Genprex, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Toscano Jose Antonio Moreno Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+37.71%
|
-
|
|
Dec 05
2024
|
Ryan M. Confer President, CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
29,375
+42.88%
|
-
|
|
Dec 05
2024
|
Brent M Longnecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+36.62%
|
-
|
|
Dec 05
2024
|
William R Wilson Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,750
+37.71%
|
-
|
|
Dec 05
2024
|
Mark Stanley Berger Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,250
+44.18%
|
-
|
|
Feb 18
2024
|
Mark Stanley Berger Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,319
-21.53%
|
$5,276
$4.4 P/Share
|
|
Feb 18
2024
|
Ryan M. Confer President, CEO and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,126
-10.34%
|
$4,504
$4.4 P/Share
|
|
Feb 18
2024
|
John Rodney Varner Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,642
-9.11%
|
$10,568
$4.4 P/Share
|
|
Jun 27
2023
|
Toscano Jose Antonio Moreno Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+50.0%
|
-
|
|
Jun 27
2023
|
Brent M Longnecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+47.14%
|
-
|
|
Jun 27
2023
|
William R Wilson Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,795
+50.0%
|
-
|
|
Apr 21
2023
|
Catherine M Vaczy EVP GC Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+7.02%
|
$20,000
$1.07 P/Share
|
|
Apr 21
2023
|
John Rodney Varner Chairman, President and CEO |
BUY
Open market or private purchase
|
Indirect |
19,000
+47.74%
|
$19,000
$1.05 P/Share
|
|
Feb 18
2023
|
Mark Stanley Berger Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+50.0%
|
-
|
|
Feb 18
2023
|
Catherine M Vaczy EVP GC Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+50.0%
|
-
|
|
Feb 18
2023
|
Ryan M. Confer President, CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
245,000
+36.0%
|
-
|
|
Feb 18
2023
|
Hermant Kumar Chief Mfgr & Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Feb 18
2023
|
John Rodney Varner Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
625,000
+35.02%
|
-
|
|
Jul 28
2022
|
Ryan M. Confer President, CEO and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
116,973
+38.04%
|
$0
$0.02 P/Share
|
|
Apr 05
2021
|
Brent M Longnecker Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$60,000
$4.15 P/Share
|